← Back

Zhejiang Chimin Pharm Co Ltd

Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells in vitro diagnostic products and provides medical services in China and internationally. Its offerings include non-PVC soft bags in double-pipe double-valve, single-pipe single-valve, and single-pipe double-valve forms, plastic bottles, and other packaging; injection puncture medical devices such as safety syringes, safety injection needles, sterile syringes, irrigators, dispensers, insulin syringes, infusion sets, and precision filter infusion sets; in vitro diagnostics products including clinical chemical, immunological, blood testing, rapid diagnostic, and enzyme-linked immunological diagnostic reagents, laboratory instruments, and in vitro diagnostic medical products, as well as FOB fecal occult blood automated immunoassay monitoring and pylori Helicobacter detection kits; and hemodialysis series products including hemodialysis concentrate, along with medical and health services. The company was formerly known as Zhejiang Chimin Pharmaceutical Co.,Ltd. and changed its name to Chimin Health Management Co., Ltd. in August 2018. Founded in 1996, it is based in Taizhou, China.

Price · split & dividend adjusted
News & notes moving 603222.CG
603222.CG▼

Jimin Health reports net loss of 49.423 million yuan in 2026 interim results

Jimin Health released its 2026 interim report. During the reporting period, the company's total operating revenue was 338 million yuan, down 7.86 percent year on year, and net profit attributable to the parent company was a loss of 49.423 million yuan. Net cash inflow from operating activities was 12.5691 million yuan, the asset-liability ratio was 46.93 percent, gross margin was 36.32 percent, return on equity was negative 4.54 percent, and diluted earnings per share was negative 0.10 yuan. The company had 33,800 shareholders, and the top ten shareholders held 45.59 percent of the shares.
603222.CG ▼
Jiemian·24dRead more →
603222.CG▼2

Jimin Health's controlling shareholder terminates transfer of 6.86% stake just two days after signing agreement

Jimin Health's controlling shareholder, Shuangge Group, has terminated the transfer of 36 million unrestricted tradable shares to Jiaxin Private Equity, representing 6.86% of the company's total share capital, for a consideration of 297 million yuan. The two parties signed the share transfer agreement on July 20, 2026, and agreed to rescind it just two days later, with all rights and obligations under the original agreement ceasing immediately. In light of the termination, Gong Guohui, head of the core management team at Great Wall Galaxy, has committed that within six months from the announcement of the asset purchase, he and core employees of Great Wall Galaxy will increase their shareholding in the company by 1% to 2% through block trades or secondary market purchases. In the first quarter of 2026, Jimin Health recorded revenue of 163 million yuan and a net loss attributable to the parent company of 25.92 million yuan.
603222.CG ▼
财中社·59dRead more →
603222.CG▲5

Jimin Health Plans to Invest 409 Million Yuan in Great Wall Galaxy, with Appraisal Value Increase Rate Reaching 260%

Jimin Health plans to pay 409 million yuan in cash to acquire part of the partnership shares of CLP Huizhi, thereby indirectly holding 20.4550% of the shareholder equity of Great Wall Galaxy and enjoying 30% voting rights. Great Wall Galaxy is an integrated circuit design company. With March 31, 2026 as the appraisal base date, the book value of all its shareholders' equity was 579 million yuan, and the appraisal result under the income approach was 2.088 billion yuan, with an appraisal value increase of 1.509 billion yuan and an increase rate of 260.86%. In the first quarter of 2026, Great Wall Galaxy's net profit was negative 9.4572 million yuan, mainly due to the provision of 64.8731 million yuan for bad debts on accounts receivable from a major customer. Excluding this impact, the net profit was 47.6224 million yuan. Jimin Health stated that this investment will open up a high-value-added business track and enhance profitability and competitiveness.
603222.CG ▲
读创财经·61dRead more →
© 2026 MarketDXAsset